Home | Welcome to Contract Pharma   
Last Updated Wednesday, August 27 2014
Print

PAREXEL Acquires ATLAS



Published July 2, 2014
PAREXEL has acquired ATLAS Medical Services, a provider of clinical research services in Turkey, the Middle East, and North Africa. ATLAS provides services for all phases of clinical development, along with study planning and feasibility, site selection, data management, and medical writing, and has therapeutic expertise in oncology, hematology, endocrinology, cardiovascular, anesthesiology, infectious diseases and the central nervous system. The firm also provides regulatory services to support product registration.
 
ATLAS, headquartered in Istanbul, has 35 employees, with additional offices in Ankara and Izmir. Its 2013 revenues were approximately $4 million.
 
Josef von Rickenbach, chairman and chief executive officer of PAREXEL said, "The acquisition of ATLAS strengthens PAREXEL's presence in Turkey, the Middle East and North Africa. These markets are of increasing importance to our clients who are looking for market access and a broad spectrum of patient populations for clinical trials. In addition, ATLAS has been a trusted business partner to PAREXEL for many years, and their infrastructure and staff are already aligned with our processes and operations. By fully integrating ATLAS into PAREXEL's global operations, we will enhance our ability to help clients more quickly achieve their goals of bringing important therapies to patients not only in Turkey, the Middle East, and North Africa, but also throughout the rest of the world."
 


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On